Safety of ustekinumab in inflammatory bowel diseases (IBD): pooled safety analysis through 5 years in Crohn's disease (CD) and 2 years in ulcerative colitis (UC)

被引：0
|
作者：
Ghosh, Subrata [1 ]
Ott, Elyssa [2 ]
Gasink, Christopher [2 ]
Miao, Ye [3 ]
Colombel, Jean-Frederic [4 ]
机构：
[1] Univ Calgary, Calgary, AB, Canada
[2] Janssen Sci Affairs LLC, Horsham, PA USA
[3] Janssen Res & Dev LLC, Spring House, PA USA
[4] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2021年 / 36卷
关键词：
ustekinumab; IBD; safety; MACE;
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
PP-0097
引用
收藏
页码：107 / 107
页数：1
相关论文
共 50 条
  • [41] Inflammatory Bowel Diseases (Crohn´s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications
    Marina Kostić
    Ljiljan Djakovic
    Raša Šujić
    Brian Godman
    Slobodan M. Janković
    Applied Health Economics and Health Policy, 2017, 15 : 85 - 93
  • [42] Integrated Safety Analysis of Vedolizumab for the Treatment of Ulcerative Colitis or Crohn's Disease
    Colombel, Jean-Frederic
    Sands, Bruce E.
    Feagan, Brian G.
    Loftus, Edward V.
    Sankoh, Serap
    Fox, Irving
    Parikh, Asit
    Milch, Catherine
    GASTROENTEROLOGY, 2013, 144 (05) : S113 - S113
  • [43] Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension
    Abreu, Maria T.
    Rowbotham, David S.
    Danese, Silvio
    Sandborn, William J.
    Miao, Ye
    Zhang, Hongyan
    Tikhonov, Ilia
    Panaccione, Remo
    Hisamatsu, Tadakazu
    Scherl, Ellen J.
    Leong, Rupert W.
    Arasaradnam, Ramesh P.
    Afif, Waqqas
    Peyrin-Biroulet, Laurent
    Sands, Bruce E.
    Marano, Colleen
    JOURNAL OF CROHNS & COLITIS, 2022, 16 (08): : 1222 - 1234
  • [44] Aberrant responses to TLR (Toll-Like-Receptor) agonists and common luminal antigens (Ags) in patients with inflammatory bowel diseases (IBD); Difference between Crohn's disease (CD) and ulcerative colitis (UC)
    Jyonouchi, Harumi
    Monteiro, Iona M.
    Geng, Lee
    Cushing-Ruby, Agnes
    GASTROENTEROLOGY, 2007, 132 (04) : A223 - A223
  • [45] Is serology for ulcerative colitis and Crohn's disease an improvement on existing screening tests for inflammatory bowel disease (IBD) in children?
    Khan, K
    Ferrenci, D
    Schwarzenberg, SJ
    Kennedy, M
    Ramalingham, A
    Stafford, R
    Greenwood, D
    Weisdorf, S
    GASTROENTEROLOGY, 2001, 120 (05) : A274 - A274
  • [46] The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data
    Cohen, Russell D.
    Bhayat, Fatima
    Blake, Aimee
    Travis, Simon
    JOURNAL OF CROHNS & COLITIS, 2020, 14 (02): : 192 - 204
  • [47] Indirect costs of inflammatory bowel diseases: Crohn's disease and ulcerative colitis. A systematic review
    Kawalec, Pawel
    ARCHIVES OF MEDICAL SCIENCE, 2016, 12 (02) : 295 - 302
  • [48] Active Tuberculosis and Opportunistic Infections: Pooled Safety Analysis of Ustekinumab Through up to 5 Years Across All Approved Indications
    Loftus, Edward V.
    Long, Millie
    Ott, Elyssa
    Gasink, Christopher
    Baker, Thomas
    Goodwin, Bridget
    Miao, Ye
    Ghosh, Subrata
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S675 - S675
  • [49] Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indications
    Ghosh, S.
    Long, M.
    Ott, E.
    Gasink, C.
    Baker, T.
    Godwin, B.
    Miao, Y.
    Loftus, E.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 681 - 681
  • [50] Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies (vol 27, pg 994, 2021)
    Patel, Chirag
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (07) : 1175 - 1175
12345